Some of the names on the move ahead of the open.» Read More
U.S. stock futures were higher this morning, as global markets shot up, following the decision by Japan's central bank to adopt negative interest rates for the first time ever.
THOUSAND OAKS, Calif. _ Amgen Inc. on Thursday reported fourth-quarter earnings of $1.8 billion. Amgen expects full-year earnings in the range of $10.60 to $11 per share, with revenue in the range of $22 billion to $22.5 billion. Amgen shares have dropped roughly 9 percent since the beginning of the year, while the Standard& Poor's 500 index has declined slightly...
TRENTON, N.J.— Capping an enviable year, Amgen's fourth-quarter profit soared 39 percent, as the biologic drugmaker posted higher revenue for nearly all its medicines. The company's results trounced analyst expectations for the fifth-straight quarter, and Amgen boosted its 2016 financial forecast. The Thousand Oaks, California- based company said Thursday...
U.S. stocks closed higher Thursday, as oil gains and Facebook outweighed pressure from declines in biotech stocks and concerns about economic growth.
U.S. stock index futures indicated a mixed open Thursday after December durable goods orders declined far more than expected.
Investors will turn their attention this week to the Fed and big earnings for clues on market direction.
Goldman Sachs Chief Equity Strategist David Kostin expects Alphabet, Bristol Myers-Squibb, Starbucks, Visa and Amgen to show good topline sales growth and better margins.
RBC Capital Markets analyst Michael Yee says there are three biotech stocks to own next year no matter how the sector performs in 2016.
Uri Gruenbaum, CEO of TipRanks, listed the top 10 biotech analysts on Wall Street based on the returns they've generated since 2009.
Some of the names on the move ahead of the open.
U.S. stock futures were sharply higher this morning, ahead of what's expected to be the first Fed interest rate hike since June 2006.
Check out the companies making headlines after the bell Tuesday: Amgen, Advanced Auto Parts, Lumber Liquidators & more.
*Kennametal, 3 M slump after forecast cuts. *Valeant up on distribution deal with Walgreens. "It's been hard to predict where the market is going on a day-to-day basis," said Scott Brown, chief economist at Raymond James in St. Petersburg, Florida.
*Kennametal, 3 M slump after forecast cuts. *Qualcomm up on raised guidance. *Valeant up on distribution deal with Walgreens.
*Traders see an 83 percent chance of a rate hike this week, according to the CME Group's FedWatch program. *Amgen shares were up nearly 3 percent at $162.70 in premarket trading. *Kennametal slumped 17 percent to $21.22 after it cut its 2016 profit and revenue forecasts, citing weakness and volatility in its core markets and lower oil prices.
Dec 14- Amgen Inc on Monday said it had reached a deal with British drugmaker GlaxoSmithKline to reacquire the sales rights to three of its products in 48 countries, including Australia as well as markets in Asia, South America and Europe. Amgen will make undisclosed milestone payments to Glaxo upon signing and the successful transition of the products back to...
NEW YORK, Dec 10- When health insurer Humana Inc reported worse-than-expected quarterly earnings in late 2014- including a 21 percent drop in net income- it softened the blow by immediately telling investors it would make a $500 million share repurchase. It added around two cents to the company's annual earnings per share, allowing Humana to surpass its $7.50...
Goldman's Robert Boroujerdi presented seven future theme predictions and their investment implications in a note to clients Wednesday.
Mark Newton, chief technical analyst at Greywolf Execution Partners, shares his top investment idea for the months ahead.
NEW YORK, Nov 23- U.S. drug benefit manager CVS Health said on Monday it would add Amgen Inc's Repatha cholesterol treatment to its list of covered drugs for private plans over a competing treatment from Regeneron Pharmaceuticals and Sanofi SA. The FDA approved Repatha and Praluent, made by Regeneron and Sanofi, within weeks of each other last summer for patients...